Daniel Pollyea, MD, shares results from an early, phase Ib study of venetoclax plus decitabine or azacitidine in older patients with treatment-naïve acute myeloid leukemia.
Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML
